M.T. Tauber*, C. Pienkowski*, F. Landier, R. Gunnarson* and P. Rochiccioli



96

Department of Paediatric Endocrinology, CHU Rangueil - 31054 Toulouse - France - Laboratoire Kabi Vitrum France and Sweden. NODIFICATION OF 24 HOUR GROWTH HORMONE (GH) SECRETION AFTER CONTI-NUOUS SUBOUTANEOUS INJECTION (CSI) OF GRF (1-29) NHO DURING 3 WEEKS IN 6 CHILDREN WITH PARTIAL OH DEFICIENCY.

6 children (2 boys and 4 girls) with growth retardation ($m = 2.8 \pm 0.5$ DS) were studied: mean chronological age was 11.9 \pm 1.5 yr, mean bone age 9.3 \pm 1.2 yr ; they were all Tanner stage I for pubertal development; GH peak after 2 pharmaco-logical tests were between 7 and 10 ng/ml, IC of GH was below 3 ng/ml/min. After an IV bolus of 1 ug/bw of GRF (1-29) NH2, mean maximum GH peak was 30 ± 13 ng/ml ranging from 15 to 50 ng/ml. 24 hour GH secretion was studied before treatment and after one and 21 days of CSI of GFF. Travenol AS 8MP pumps were used, catheter and syringes were previously tested for GFF achesion. The dose of GFF used was either 20 or 40 ug/bw/day. On day one, mean 24 hour IC of GH increased from 2.3 \pm 0.4 to 5.7 \pm 3.3 ng/ml/min, maximum GH peak from 13 \pm 4 to 35 \pm 20 ng/ml and the number of GH peaks above 5 ng/ml rose from 3.7 \pm 0.8 to 6.8 \pm 3.3. Among the 3 children (1 boy and 2 girls) receiving 20 ug/bw/day of GFF, only one increased his 24 hour IC of GH up to 3 ng/ml/min (from 2.31 to 4.74 ng/ml/min), but this result was obtained in the 3 children receiving 40 ug/bw/day. After 21 days of such treatment the mean value of 24 hour IC of CH was 5.2 ± 3.3 ng/ml/min, the mean maximum CH peak 28 ± 18 ng/ml and the mean number of CH peaks was 7.5 ± 2.9 . In all but one child, the response to GFF (1-29) NH2 decreased whatever the dose used but the 24 hour IC of GH remained above 3 ng/ml/min when this value was obtained on day one. Local and general tolerance was good.

In conclusion : the effect on 24 hour GH secretion after CSI of CRF (1-29) NH2 depend on the dose, normalization of 24 hour IC of GH was obtained in all cases when the dose was 40 ug/bw/day, this effect decreased after 21 days.

J.O.L. Jørgensen*, A. Flyvbjerg*, T. Lauritzen *, H. Ørskov*, J.S. Christiansen* (Introd. by N.E. Skakkebæk).

Skakkebæk). Second University Clinic of Internal Medicine, Aarhus Kommunehospital, DK-8000 Aarhus C, Denmark. DOSE-RESPONSE STUDIES WITH BIOSYNTHETIC HUMAN GROWTH HORMONE IN GROWTH HORMONE DEFICIENT PATIENTS.

DOSE-RESPONSE STUDIES WITH BIOSYNTHETIC HUMAN GROWTH HORMONE IN GROWTH HORMONE DEFICIENT PATIENTS. Increasing doses of biosynthetic human growth hormone (B-hGH) were given subcutaneously to 7 GH deficient subjects for three 14 days periods (2, 4 and 6 IU/day at 20.00 h) followed by 14 days without GH therapy. At the end of each period they were hospitalized for blood sampling. A dose-dependent increase in serum GH and somatomedin-C (Sm-C) levels occurred. However, the time course of the serum Sm-C patterns showed a significant increase following inflections of 2 IU of B-hGH, and constant levels with-in normal range during treatment with 4 and 6 IU. Plasma glucose was within normal range, with lower fasting levels (at 04.00 h) when no GH was given. Breakfast induced a plasma glucose rise when GH was administered, but no rise without GH, and a dose-dependent increase in the post-prandial insulin response. GH therapy increased serum levels of free fatty acids (p < 0.05) and 3-OH-butyrate but had no significant impact on serum trigly-ceride and cholesterol. We conclude that serum Sm-C levels show consistent GH dose-dependence, and that a GH replacement dose of 2 IU/day (1.5 IU/m²/day) is insufficient to maintain normal diurnal levels. Furthermore, a GH independent diurnal variation in these patients is suggested, and finally it is demonstrated in these patients is suggested, and finally it is demonstrated that this authentic GH preparation possesses diabetogenic and lipolytic actions.

97

J.O.L. Jørgensen*, J. Møller*, T. Lauritzen*, <u>J.S.</u> <u>Christiansen*</u> (Introd. by N.E. Skakkebæk). Second University Clinic of Internal Medicine, Aarhus Kommunehospital, Denmark. THE ABSORPTION KINETICS OF SUBCUTANEOUSLY ADMINISTE-RED GROWTH HORMONE: INFLUENCE OF INJECTION VOLUME.

RED GROWTH HORMONE: INFLUENCE OF INJECTION VOLUME. Daily subcutaneous (sc) injections (inj) seems now to be the recommended mode of GH administration. A substantial sc degrada-tion of exogenous GH has previously been reported. The aim of the present study was to evaluate the influence of inj volume on the sc absorption rate and bioavailability of GH. Fourteen heal-thy adults with a median age of 27.5 years and a normal body mass index participated. In a randomized design they all recei-ved 3 sc inj of 6 IU biosynthetic human GH (Norditropin^R) dis-solved in either 0.5, 1.0 or 2 ml respectively. At least one week elapsed between each inj, which was given in the morning (8,00h) after which moderate physical activity was allowed. Blood was sampled hourly for 7 (n=14) to 12 (n=8) hours. The initial absorption rate (2 hour values) tended to be faster with the 2 ml inj volume (P=6.5%). The 2 ml inj volume also yielded the highest mean peak GH values: 23.7 ng/ml (2 ml), 14.7 ng/ml (1 ml) and 16.9 ng/ml (0.5 ml) (P<0.02), as well as the largest area under the curves (8-15 hours): 89.6 ngxhour/ml (2 ml), 62.7l ngxhour/ml (1 ml) and 67.8 ngxhour/ml (P<0.05). We therefore conclude that a large inj volume could imply a more rapid ab-sorption as well as a larger bioavailability of sc inl GH. One could speculate that a rapid sc absorption diminishes the local degradation of GH and thus increases its bioavailability.

98

99

P.Saenger*Y.St.Louis*, R.Wu*, J.DiMartino-Nardi*, S. Breidbart*, M. Thorpy*, B. Sherman*, E. Sobel, Dept. Peds Montefiore Med. Ctr., A. Einstein Coll. Med., Bronx, N.Y. Clin.Res.Div., Genentech.Inc., So.San Francisco, Calif. PRESERVATION OF PHYSIOLOGIC SECRETION OF GROWTH HOR-MONE DURING TREATMENT OF IDIOPATHIC SHORT STATURE WITH GROWTH HORMONE (rhGH).


Twenty four hour secretory profiles of growth hormone were measured in 3 children with idiopathic short stature before and 48 hours after 6 months of treatment with rhGH. The study was undertaken to assess the possibility that exogenous GH might imundertaken to assess the possibility that exogenous on might im-pair endogenous secretion. The children were all prepubertal (mean age 10.5yr±.8), with GH levels greater than 10 ng/ml on provocative testing. Growth velocity during therapy increased from a mean of $3.8t_1.5$ to 7.0±1.5cm/yr, (p<0.001). The repeat studies were carried out under identical conditions in the sleep laboratory. Total sleep time verified by sleep polysomnography and EEG recordings was id-entical in both studies (mean 503 vs 505 minutes). Comparison of pre and post treatment GH secretory profiles showed no attenuation of endogenous GH levels. Between pulses GH concentration was un-dectable in the pre and post rhGH treatment study.

facetable in the pre and post then treatment brady.						
	Serum	GH conc.	GH peaks	Serum	GH conc.	GH peaks
	before	rhGH	(n)	after	rhGH	(n)
	mean	conc.ofp	001	mean	conc.ofpo	01
	(ng/ml)	(ng/m1)	(ng/ml)(ng/ml)			
Patient	1 2.2	2.6	7	2.0	1.8	6
Patient	2 0.9	0.8	2	1.3	1.0	3
Patient	3 3.1	2.3	6	5.6	5.3	5
We conclude that exogenous therapy does not interfere with main- tenance of endogenous pulsatile secretion of GH. These data pro- the crowing child, the resilience of the GH secretory system in the crowing child.						
tenance,	of endog	enous pul	satile secre	tion of	f GH. Thes	e data pro-
Ithe erow	The chil	L LUE FES	ritence of f	me Gn :	secretory	system in

H.P.Schwarz, S.C.Duck[#], D.T.Wyatt[#], A.H.Kissebah[#]. Department of Pediatrics and Clinical Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin USA. TREATMENT OF SHORT NORMAL PREPUBERTAL CHILDREN WITH

GROWTH HORMONE.

The growth reponse to growth hormone (GH) was studied in 9 short normal prepubertal children (6 boys, 3 girls) with a low height velocity. Their average age was 8.2yr (range 4.7-12.1), height standard deviation score (SDS) for chronologi-cal age (CA) was -2.6 (-2.0 to -3.7). All had normal maximum plasma GH responses above 10ng/mL to stimulation with cloniding plasma GH responses above 10ng/mL to stimulation with clonidine and/or insulin induced hypoglycemia. Assessment of overnight GH secretion by measurement of GH in 20min intervals for 12h yielded low peak levels of $8.7\pm3.0(SD)ng/mL$ and low mean pool values of 1.9 ± 1.0 . With informed consent treatment with somatrem (Protropin) $0.11\pm0.01mg/kg$ three times weekly s.c. was then begun and continued for one year. No major side effects were noted. After 6 months of GH therapy, height velocity SDS for CA increased significantly (p<0.001) from a pretreatment mean of -1.7 (-0.6 to -3.0) to +3.4 (-1.0 to +5.7), representing a change from 4.7cm/yr (3.5-6.0) to 9.3 (5.7-12.5). Height velocity during GH treatment (SDS for CA and cm/yr) inversely correlated with endogenous nocturnal peak GH conceninversely correlated with endogenous nocturnal peak GH concentration (r=-0.76, and r=-0.78; both p<0.05). We conclude that some short normal children with low height velocity and low endogenous GH secretion may profit from GH therapy. A major goal should be the proper identification of these patients and careful long-term follow-up to final height. Supported by Genentech, Inc., South San Francisco, California.



treatment.

Used in appropriate dosage, both agents are safe, simple and effective agents in Turner syndrome. Neither appears to work via increased CH secretion.